Granules India Ltd Board of Directors
Board of Directors at Granules India Ltd
Non-Exec. & Independent Dir.
Chairman & Managing Director
Company Sec. & Compli. Officer
Executive Director
Non-Exec & Non-Independent Dir
Key Highlights
- C Krishna Prasad continues to serve as the CMD & Executive Director in 2026, maintaining the same position as in the previous year.
- Uma Devi Chigurupati continues to serve as the ED (Non-Independent) in 2026, maintaining the same position as in the previous year.
- Harsha Chigurupati continues to serve as the ED (Non-Independent) in 2026, maintaining the same position as in the previous year.
- Priyanka Chigurupati joins the board as Executive Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- K B Sankara Rao joins the board as Non-Exec & Non-Independent Dir, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
Granules India Ltd
NSE: GRANULES
Share Price
Last Ten Days Market Price
| Date | |
|---|---|
| 05 Oct 2026 | 816.7 |
| 01 Oct 2026 | 820.8 |
| 30 Sep 2026 | 847.35 |
| 29 Sep 2026 | 867.7 |
| 28 Sep 2026 | 849.15 |
| 25 Sep 2026 | 871.35 |
| 24 Sep 2026 | 853.5 |
| 23 Sep 2026 | 860 |
| 22 Sep 2026 | 864.5 |
| 21 Sep 2026 | 875.45 |
Company Fundamentals for Granules India Ltd
Market Cap
22,277 Cr
EPS
23.8
P/E Ratio (TTM)
34.3
P/B Ratio (TTM)
3.6
Day’s High
832.0
Day’s Low
815.0
DTE
0.3
ROE
11.7
52 Week High
922.1
52 Week Low
520.05
ROCE
13.6
Market Price of Granules India Ltd
1M
1Y
3Y
5Y
Granules India Ltd News Hub
Granules India Ltd soars 1.63%, up for third straight session
Granules India Ltd rose for a third straight session today. The stock is quoting at Rs 686.45, up 1.
Read more
21 Aug 24
Granules Pharmaceuticals receives USFDA approval for Glycopyrrolate Oral Solution
Granules India announced today that the U.S. Food and Drug Administration (FDA) has approved its Abb
Read more
20 Aug 24
Granules India rises on USFDA nod for oral drug Glycopyrrolate
The ANDA has been filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary o
Read more
20 Aug 24
Granules India receives US FDA nod for depression treatment drug Trazodone
It is bioequivalent and therapeutically equivalent to the reference listed drug Desyrel Tablets of P
Read more
09 Aug 24
Document
Concalls
